A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Neurological Research

• Publication date

  2010-03-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1179/016164109X12590518685660PMID 20307378
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FUNCTIONAL EVALUATION: THE BARTHEL INDEX.

  2018cited by this paper
• Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial.

  2008cited by this paper
• Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.

  2007cited by this paper
• Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis

  2007cited by this paper
• Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double‐blind, placebo‐controlled clinical trial

  2007cited by this paper
• A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.

  2006cited by this paper
• Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

  2006cited by this paper
• Regional variations in the prevalence of multiple sclerosis in French farmers

  2006cited by this paper
• Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

  2005cited by this paper
• Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up

  2005cited by this paper
• Prevalence and treatment of spasticity reported by multiple sclerosis patients

  2004cited by this paper
• Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

  2004cited by this paper
• Clinical and immunological findings in patients with concurrent MS and autoimmune thyroid disease

  2004cited by this paper
• Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

  2004cited by this paper
• A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

  2003cited by this paper
• Anti-spasticity agents for multiple sclerosis.

  2003cited by this paper
• Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial

  2003cited by this paper
• Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.

  2003cited by this paper
• Treatments for spasticity and pain in multiple sclerosis: a systematic review.

  2003cited by this paper
• Endocannabinoids control spasticity in a multiple sclerosis model

  2001cited by this paper
• Cannabinoids control spasticity and tremor in a multiple sclerosis model

  2000cited by this paper
• Neuropharmacology and therapeutic potential of cannabinoids

  2000cited by this paper
• What is meant by intention to treat analysis? Survey of published randomised controlled trials

  1999cited by this paper
• A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity

  1999cited by this paper
• Modeling valuations for EuroQol health states.

  1997cited by this paper
• Pharmacology of cannabinoid CB1 and CB2 receptors.

  1997cited by this paper
• EuroQol: the current state of play.

  1996cited by this paper
• A health-related quality of life measure for multiple sclerosis

  1995cited by this paper
• High‐dose oral baclofen

  1991cited by this paper
• EuroQol : a new facility for the measurement of health-related quality of life

  1990cited by this paper
• EuroQol--a new facility for the measurement of health-related quality of life.

  1990cited by this paper
• Clinical applications of visual analogue scales: a critical review

  1988cited by this paper
• The Barthel ADL Index: a reliability study.

  1988cited by this paper
• Interrater reliability of a modified Ashworth scale of muscle spasticity.

  1987cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• FUNCTIONAL EVALUATION: THE BARTHEL INDEX.

  1965cited by this paper

• Translational molecular imaging and drug development in multiple sclerosis

  2026cites this paper
• Nabiximols improves sleep architecture in multiple sclerosis: A prospective polysomnographic study.

  2026cites this paper
• Cannabis-based medicines for chronic neuropathic pain in adults.

  2026cites this paper
• Maintaining Mobility and Balance in Multiple Sclerosis: A Systematic Review Examining Potential Impact of Symptomatic Pharmacotherapy

  2025cites this paper
• A randomized trial on efficacy of purified cannabidiol on spasticity in multiple sclerosis patients with gait problems: first report in Iran

  2025cites this paper
• Marijuana Use in a Nationwide Survey of Burn Survivors.

  2025cites this paper
• The CB2 Receptor in Immune Regulation and Disease: Genetic Architecture, Epigenetic Control, and Emerging Therapeutic Strategies

  2025cites this paper
• Cannabinoids for Treating Sleep

  2025cites this paper
• Understanding Depression in People Living with Multiple Sclerosis: A Narrative Review of Recent Literature

  2025cites this paper
• Phytocanabinoids and synthetic cannabinoids: from recreational consumption to potential therapeutic use – a review

  2025cites this paper
• Cannabinoids for spasticity in patients with multiple sclerosis: A systematic review and meta-analysis

  2024cites this paper
• Disease-Modifying Symptomatic Treatment (DMST) Potential of Cannabinoids in Patients with Multiple Sclerosis

  2024cites this paper
• Nabiximols (NBX) suppresses tremor in a rat Harmaline model of essential tremor.

  2024cites this paper
• Palliative care aspects in multiple sclerosis.

  2024cites this paper
• Effectiveness, Safety and Patients’ Satisfaction of Nabiximols (Sativex®) on Multiple Sclerosis Spasticity and Related Symptoms in a Swiss Multicenter Study

  2024cites this paper
• Practical tool to identify Spasticity-Plus Syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis

  2024cites this paper
• Effect of nabiximols oromucosal spray (Sativex®) on symptoms associated with multiple sclerosis-related spasticity: a case series

  2024cites this paper
• GPCR kinase subtype requirements for arrestin-2 and -3 translocation to the type-1 cannabinoid receptor and the consequences on G protein signalling.

  2024cites this paper
• Narrative bias ("spin") is common in randomised trials and systematic reviews of cannabinoids for pain.

  2024cites this paper
• Spasticity-Plus syndrome in multiple sclerosis patients in a tertiary hospital in Spain

  2024cites this paper
• The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of Sativex® - A Cannabis-derived Spray.

  2024cites this paper
• Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy

  2023cites this paper
• Cannabis-Based Medicine for Neuropathic Pain and Spasticity—A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial

  2023cites this paper
• Cannabis products: medical use

  2023cites this paper
• Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis

  2023cites this paper
• Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials

  2023cites this paper
• A post hoc evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols

  2023cites this paper
• Suicidality risk after using cannabis and cannabinoids: An umbrella review

  2023cites this paper
• Nabiximols oromucosal spray in patients with multiple sclerosis-related bladder dysfunction: A prospective study.

  2023cites this paper
• Cannabinoids in Symptomatic Treatment for People with Multiple Sclerosis: a Systematic Review of Randomised Studies

  2023cites this paper
• A type II cannabis extract and a 1:1 blend of Δ(9)-tetrahydrocannabinol and cannabidiol display distinct antinociceptive profiles and engage different endocannabinoid targets when administered into the subarachnoid space

  2023cites this paper
• Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions

  2023cites this paper
• Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.

  2023cites this paper
• Cannabis and sleep disorders: not ready for prime time? A qualitative scoping review

  2023cites this paper
• Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases

  2023cites this paper
• The Neurotoxic Effects of Cannabis on Brain: Review of Clinical and Experimental Data

  2022cites this paper
• Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis

  2022cites this paper
• Use of Cannabidiol in the Management of Insomnia: A Systematic Review

  2022influential citation
• The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms

  2022cites this paper
• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.

  2022cites this paper
• Efficacy of cannabis and its constituents in disease management: Insights from clinical studies.

  2022cites this paper
• Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination

  2022cites this paper
• Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders

  2022cites this paper
• Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications

  2022influential citation
• A real‐world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described ‘spasticity‐plus syndrome’

  2022cites this paper
• Sistema endocannabinoide y el rol del cannabis medicinal en el tratamiento de la espasticidad: una revisión narrativa

  2022cites this paper
• Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice

  2022cites this paper
• Effects of Sativex® on cognitive function in patients with multiple sclerosis: A systematic review and meta-analysis.

  2022cites this paper
• Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience

  2021cites this paper
• Cannabinoid Activity—Is There a Causal Connection to Spasmolysis in Clinical Studies?

  2021cites this paper
• Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials

  2021cites this paper
• Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years” accumulated evidence from clinical trials

  2021cites this paper
• Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol

  2021cites this paper
• Cannabidiol and Other Cannabinoids in Demyelinating Diseases

  2021cites this paper
• Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses

  2021cites this paper
• Medical Cannabis and Cannabinoids for Impaired Sleep: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

  2021cites this paper
• Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity

  2021cites this paper
• TIBBİ KENEVİR VE SAĞLIK: FARMAKOLOJİK BİR DERLEME

  2021cites this paper
• Cannabinoids in Neurologic Illnesses.

  2021cites this paper
• Cannabinoids and Neuropsychiatric Disorders

  2021influential citation
• Nabiximols in chronic neuropathic pain: a meta-analysis of randomized placebo-controlled trials.

  2021cites this paper
• Non-invasive brain stimulation to assess neurophysiologic underpinnings of lower limb motor impairment in multiple sclerosis.

  2021cites this paper
• Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat® Methodology

  2021cites this paper
• Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations.

  2021cites this paper
• Nabiximols (Sativex®)

  2021cites this paper
• Minimally Invasive Surgery for Chronic Pain Management: An Evidence-Based Approach

  2020cites this paper
• Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use?

  2020cites this paper
• Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study

  2020cites this paper
• Current state of knowledge on the use of medical marijuana in some neurological diseases

  2020cites this paper
• Clinical assessment, management and rehabilitation of walking impairment in MS: An Expert Review.

  2020cites this paper
• EAN guideline on palliative care of people with severe, progressive multiple sclerosis

  2020cites this paper
• Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature

  2020cites this paper
• Therapeutic Uses of Cannabis on Sleep Disorders and Related Conditions.

  2020cites this paper
• Cannabis and Multiple Sclerosis.

  2020cites this paper
• Immune Responses Regulated by Cannabidiol

  2020cites this paper
• Application of Cannabinoids in Neurosciences

  2020cites this paper
• The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiple sclerosis

  2020cites this paper
• The molecular mechanisms that underpin the biological benefit of full spectrum cannabis extract in the treatment of neuropathic pain and inflammation.

  2020cites this paper
• The Broad Concept of “Spasticity-Plus Syndrome” in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms

  2020cites this paper
• A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain

  2020cites this paper
• Toxicological Properties of Δ9-tetrahydrocannabinol and Cannabidiol

  2020cites this paper
• Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis

  2020cites this paper
• Safety Considerations in Cannabinoid-Based Medicine

  2020cites this paper
• Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study

  2020cites this paper
• Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials.

  2020cites this paper
• Is time elapsed between cannabis use and sleep start time associated with sleep continuity? An experience sampling method.

  2020cites this paper
• Cannabinoid-Based Medicines and Multiple Sclerosis.

  2020cites this paper
• Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Medical Cannabis and Cannabis-based Medicines for Chronic Noncancer Pain

  2020cites this paper
• Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial

  2020cites this paper
• Cannabinoids in Neurologic Conditions

  2020cites this paper
• EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis

  2020influential citation
• Cannabidiol metabolism revisited: tentative identification of novel decarbonylated metabolites of cannabidiol formed by human liver microsomes and recombinant cytochrome P450 3A4

  2019cites this paper
• Cannabinoids for the treatment of spasticity

  2019cites this paper
• Considering abuse liability and neurocognitive effects of cannabis and cannabis-derived products when assessing analgesic efficacy: a comprehensive review of randomized-controlled studies

  2019cites this paper
• Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology

  2019cites this paper
• Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders.

  2019cites this paper
• Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

  2019cites this paper
• Wirksamkeit, Verträglichkeit und Sicherheit von medizinischem Cannabis

  2019cites this paper
• Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies

  2019cites this paper
• Advances in the Understanding and Management of Chronic Pain in Multiple Sclerosis: a Comprehensive Review

  2019cites this paper